Evaluating Acridones as Novel Therapeutics for Human Babesiosis
Acridone derivatives show strong <i>in vitro</i> antibabesial activity and represent promising lead chemotypes for therapeutic development. To advance these candidates, future studies focused on optimizing their pharmacokinetic properties, improving in vivo efficacy, and evaluating synergistic combination regimens will be essential for progressing toward effective treatments for human babesiosis.
Authors
- Choukri Ben Mamoun (ORCID: https://orcid.org/0000-0001-5028-1400)
- Pratap Vydyam (ORCID: https://orcid.org/0000-0003-4944-6006)
- Jane X. Kelly (ORCID: https://orcid.org/0000-0001-8871-0207)
- Anasuya Pal (ORCID: https://orcid.org/0000-0002-0068-8912)
- Papireddy Kancharla (ORCID: https://orcid.org/0000-0002-6381-1236)
- Rozalia A. Dodean (ORCID: https://orcid.org/0000-0001-5002-4607)
- Elizabeth Zhang (ORCID: https://orcid.org/0000-0002-1117-8635)
Institutions
- Portland State University (US)
- Veterans Health Administration (US)
- Portland VA Medical Center (US)
- Yale University (US)
- Genesis Research Institute (JP)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-01-08
- DOI
- https://doi.org/10.64898/2026.01.07.698299
- Primary Topic
- Vector-borne infectious diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00